32 results on '"Schroeder BO"'
Search Results
2. Parvimonas micra forms a distinct bacterial network with oral pathobionts in colorectal cancer patients.
- Author
-
Löwenmark T, Köhn L, Kellgren T, Rosenbaum W, Bronnec V, Löfgren-Burström A, Zingmark C, Larsson P, Dahlberg M, Schroeder BO, Wai SN, Ljuslinder I, Edin S, and Palmqvist R
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Feces microbiology, RNA, Ribosomal, 16S genetics, Mouth microbiology, Firmicutes isolation & purification, Firmicutes genetics, Fusobacterium nucleatum isolation & purification, Case-Control Studies, Microsatellite Instability, Adult, Bacteria classification, Bacteria genetics, Bacteria isolation & purification, Colorectal Neoplasms microbiology, Colorectal Neoplasms pathology
- Abstract
Background: Mounting evidence suggests a significant role of the gut microbiota in the development and progression of colorectal cancer (CRC). In particular, an over-representation of oral pathogens has been linked to CRC. The aim of this study was to further investigate the faecal microbial landscape of CRC patients, with a focus on the oral pathogens Parvimonas micra and Fusobacterium nucleatum., Methods: In this study, 16S rRNA sequencing was conducted using faecal samples from CRC patients (n = 275) and controls without pathological findings (n = 95)., Results: We discovered a significant difference in microbial composition depending on tumour location and microsatellite instability (MSI) status, with P. micra, F. nucleatum, and Peptostreptococcus stomatis found to be more abundant in patients with MSI tumours. Moreover, P. micra and F. nucleatum were associated with a cluster of CRC-related bacteria including Bacteroides fragilis as well as with other oral pathogens such as P. stomatis and various Porphyromonas species. This cluster was distinctly different in the control group, suggesting its potential linkage with CRC., Conclusions: Our results suggest a similar distribution of several CRC-associated bacteria within CRC patients, underscoring the importance of considering the concomitant presence of bacterial species in studies investigating the mechanisms of CRC development and progression., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
3. Antibiotics damage the colonic mucus barrier in a microbiota-independent manner.
- Author
-
Sawaed J, Zelik L, Levin Y, Feeney R, Naama M, Gordon A, Zigdon M, Rubin E, Telpaz S, Modilevsky S, Ben-Simon S, Awad A, Harshuk-Shabso S, Nuriel-Ohayon M, Werbner M, Schroeder BO, Erez A, and Bel S
- Subjects
- Animals, Mice, Inflammatory Bowel Diseases chemically induced, Inflammatory Bowel Diseases metabolism, Inflammatory Bowel Diseases pathology, Inflammatory Bowel Diseases microbiology, Endoplasmic Reticulum Stress drug effects, Disease Models, Animal, Fecal Microbiota Transplantation, Mice, Inbred C57BL, Humans, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents adverse effects, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Intestinal Mucosa drug effects, Intestinal Mucosa pathology, Gastrointestinal Microbiome drug effects, Colon metabolism, Colon drug effects, Colon pathology, Colon microbiology, Mucus metabolism
- Abstract
Antibiotic use is a risk factor for development of inflammatory bowel diseases (IBDs). IBDs are characterized by a damaged mucus layer, which does not separate the intestinal epithelium from the microbiota. Here, we hypothesized that antibiotics affect the integrity of the mucus barrier, which allows bacterial penetrance and predisposes to intestinal inflammation. We found that antibiotic treatment led to breakdown of the colonic mucus barrier and penetration of bacteria into the mucus layer. Using fecal microbiota transplant, RNA sequencing followed by machine learning, ex vivo mucus secretion measurements, and antibiotic treatment of germ-free mice, we determined that antibiotics induce endoplasmic reticulum stress in the colon that inhibits colonic mucus secretion in a microbiota-independent manner. This antibiotic-induced mucus secretion flaw led to penetration of bacteria into the colonic mucus layer, translocation of microbial antigens into circulation, and exacerbation of ulcerations in a mouse model of IBD. Thus, antibiotic use might predispose to intestinal inflammation by impeding mucus production.
- Published
- 2024
- Full Text
- View/download PDF
4. The gut commensal Blautia maintains colonic mucus function under low-fiber consumption through secretion of short-chain fatty acids.
- Author
-
Holmberg SM, Feeney RH, Prasoodanan P K V, Puértolas-Balint F, Singh DK, Wongkuna S, Zandbergen L, Hauner H, Brandl B, Nieminen AI, Skurk T, and Schroeder BO
- Subjects
- Animals, Mice, Humans, Male, Receptors, G-Protein-Coupled metabolism, Receptors, G-Protein-Coupled genetics, Female, Mice, Inbred C57BL, Mucus metabolism, Fecal Microbiota Transplantation, Symbiosis, Propionates metabolism, Clostridiales metabolism, Acetates metabolism, Adult, Gastrointestinal Microbiome, Dietary Fiber metabolism, Fatty Acids, Volatile metabolism, Colon metabolism, Colon microbiology, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Receptors, Cell Surface
- Abstract
Beneficial gut bacteria are indispensable for developing colonic mucus and fully establishing its protective function against intestinal microorganisms. Low-fiber diet consumption alters the gut bacterial configuration and disturbs this microbe-mucus interaction, but the specific bacteria and microbial metabolites responsible for maintaining mucus function remain poorly understood. By using human-to-mouse microbiota transplantation and ex vivo analysis of colonic mucus function, we here show as a proof-of-concept that individuals who increase their daily dietary fiber intake can improve the capacity of their gut microbiota to prevent diet-mediated mucus defects. Mucus growth, a critical feature of intact colonic mucus, correlated with the abundance of the gut commensal Blautia, and supplementation of Blautia coccoides to mice confirmed its mucus-stimulating capacity. Mechanistically, B. coccoides stimulated mucus growth through the production of the short-chain fatty acids propionate and acetate via activation of the short-chain fatty acid receptor Ffar2, which could serve as a new target to restore mucus growth during mucus-associated lifestyle diseases., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
5. A history of repeated antibiotic usage leads to microbiota-dependent mucus defects.
- Author
-
Krigul KL, Feeney RH, Wongkuna S, Aasmets O, Holmberg SM, Andreson R, Puértolas-Balint F, Pantiukh K, Sootak L, Org T, Tenson T, Org E, and Schroeder BO
- Subjects
- Humans, Animals, Mice, Intestinal Mucosa microbiology, Intestinal Mucosa metabolism, Intestinal Mucosa drug effects, Male, Female, Feces microbiology, Adult, Middle Aged, Akkermansia, Mice, Inbred C57BL, Colon microbiology, Bacteroides fragilis drug effects, Gastrointestinal Microbiome drug effects, Anti-Bacterial Agents pharmacology, Fecal Microbiota Transplantation, Mucus metabolism, Mucus microbiology, Bacteria classification, Bacteria genetics, Bacteria drug effects, Bacteria isolation & purification, Bacteria metabolism
- Abstract
Recent evidence indicates that repeated antibiotic usage lowers microbial diversity and ultimately changes the gut microbiota community. However, the physiological effects of repeated - but not recent - antibiotic usage on microbiota-mediated mucosal barrier function are largely unknown. By selecting human individuals from the deeply phenotyped Estonian Microbiome Cohort (EstMB), we here utilized human-to-mouse fecal microbiota transplantation to explore long-term impacts of repeated antibiotic use on intestinal mucus function. While a healthy mucus layer protects the intestinal epithelium against infection and inflammation, using ex vivo mucus function analyses of viable colonic tissue explants, we show that microbiota from humans with a history of repeated antibiotic use causes reduced mucus growth rate and increased mucus penetrability compared to healthy controls in the transplanted mice. Moreover, shotgun metagenomic sequencing identified a significantly altered microbiota composition in the antibiotic-shaped microbial community, with known mucus-utilizing bacteria, including Akkermansia muciniphila and Bacteroides fragilis , dominating in the gut. The altered microbiota composition was further characterized by a distinct metabolite profile, which may be caused by differential mucus degradation capacity. Consequently, our proof-of-concept study suggests that long-term antibiotic use in humans can result in an altered microbial community that has reduced capacity to maintain proper mucus function in the gut.
- Published
- 2024
- Full Text
- View/download PDF
6. Intestinal α-Defensins Play a Minor Role in Modulating the Small Intestinal Microbiota Composition as Compared to Diet.
- Author
-
Puértolas-Balint F and Schroeder BO
- Subjects
- Mice, Animals, Ileum metabolism, Ileum microbiology, Diet, Bacteria metabolism, Intestinal Mucosa microbiology, alpha-Defensins genetics, alpha-Defensins metabolism, Gastrointestinal Microbiome, Microbiota
- Abstract
The intestinal microbiota is at the interface between the host and its environment and thus under constant exposure to host-derived and external modulators. While diet is considered to be an important external factor modulating microbiota composition, intestinal defensins, one of the major classes of antimicrobial peptides, have been described as key host effectors that shape the gut microbial community. However, since dietary compounds can affect defensin expression, thereby indirectly modulating the intestinal microbiota, their individual contribution to shaping gut microbiota composition remains to be defined. To disentangle the complex interaction among diet, defensins, and small-intestinal microbiota, we fed wild-type (WT) mice and mice lacking functionally active α-defensins ( Mmp7
-/- mice) either a control diet or a Western-style diet (WSD) that is rich in saturated fat and simple carbohydrates but low in dietary fiber. 16S rDNA sequencing and robust statistical analyses identified that bacterial composition was strongly affected by diet while defensins had only a minor impact. These findings were independent of sample location, with consistent results between the lumen and mucosa of the jejunum and ileum, in both mouse genotypes. However, distinct microbial taxa were also modulated by α-defensins, which was supported by differential antimicrobial activity of ileal protein extracts. As the combination of WSD and defensin deficiency exacerbated glucose metabolism, we conclude that defensins only have a fine-tuning role in shaping the small-intestinal bacterial composition and might instead be important in protecting the host against the development of diet-induced metabolic dysfunction. IMPORTANCE Alterations in the gut microbial community composition are associated with many diseases, and therefore identifying factors that shape the microbial community under homeostatic and diseased conditions may contribute to the development of strategies to correct a dysbiotic microbiota. Here, we demonstrate that a Western-style diet, as an extrinsic parameter, had a stronger impact on shaping the small intestinal bacterial composition than intestinal defensins, as an intrinsic parameter. While defensins have been previously shown to modulate bacterial composition in young mice, our study supplements these findings by showing that defensins may be less important in adult mice that harbor a mature microbial community. Nevertheless, we observed that defensins did affect the abundance of distinct bacterial taxa in adult mice and protected the host from aggravated diet-induced glucose impairments. Consequently, our study uncovers a new angle on the role of intestinal defensins in the development of metabolic diseases in adult mice., Competing Interests: The authors declare no conflict of interest.- Published
- 2023
- Full Text
- View/download PDF
7. Autophagy controls mucus secretion from intestinal goblet cells by alleviating ER stress.
- Author
-
Naama M, Telpaz S, Awad A, Ben-Simon S, Harshuk-Shabso S, Modilevsky S, Rubin E, Sawaed J, Zelik L, Zigdon M, Asulin N, Turjeman S, Werbner M, Wongkuna S, Feeney R, Schroeder BO, Nyska A, Nuriel-Ohayon M, and Bel S
- Subjects
- Animals, Mice, Beclin-1, Mucus, Autophagy, Intestinal Mucosa microbiology, Goblet Cells, Inflammation
- Abstract
Colonic goblet cells are specialized epithelial cells that secrete mucus to physically separate the host and its microbiota, thus preventing bacterial invasion and inflammation. How goblet cells control the amount of mucus they secrete is unclear. We found that constitutive activation of autophagy in mice via Beclin 1 enables the production of a thicker and less penetrable mucus layer by reducing endoplasmic reticulum (ER) stress. Accordingly, genetically inhibiting Beclin 1-induced autophagy impairs mucus secretion, while pharmacologically alleviating ER stress results in excessive mucus production. This ER-stress-mediated regulation of mucus secretion is microbiota dependent and requires the Crohn's-disease-risk gene Nod2. Overproduction of mucus alters the gut microbiome, specifically expanding mucus-utilizing bacteria, such as Akkermansia muciniphila, and protects against chemical and microbial-driven intestinal inflammation. Thus, ER stress is a cell-intrinsic switch that limits mucus secretion, whereas autophagy maintains intestinal homeostasis by relieving ER stress., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
8. Muc2-dependent microbial colonization of the jejunal mucus layer is diet sensitive and confers local resistance to enteric pathogen infection.
- Author
-
Birchenough GMH, Schroeder BO, Sharba S, Arike L, Recktenwald CV, Puértolas-Balint F, Subramani MV, Hansson KT, Yilmaz B, Lindén SK, Bäckhed F, and Hansson GC
- Subjects
- Animals, Mice, Diet, Western, Intestine, Small, Mucus, Citrobacter rodentium physiology, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Jejunum, Mucin-2 genetics, Mucin-2 metabolism
- Abstract
Intestinal mucus barriers normally prevent microbial infections but are sensitive to diet-dependent changes in the luminal environment. Here we demonstrate that mice fed a Western-style diet (WSD) suffer regiospecific failure of the mucus barrier in the small intestinal jejunum caused by diet-induced mucus aggregation. Mucus barrier disruption due to either WSD exposure or chromosomal Muc2 deletion results in collapse of the commensal jejunal microbiota, which in turn sensitizes mice to atypical jejunal colonization by the enteric pathogen Citrobacter rodentium. We illustrate the jejunal mucus layer as a microbial habitat, and link the regiospecific mucus dependency of the microbiota to distinctive properties of the jejunal niche. Together, our data demonstrate a symbiotic mucus-microbiota relationship that normally prevents jejunal pathogen colonization, but is highly sensitive to disruption by exposure to a WSD., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Outlook on the gut microbiota.
- Author
-
Schroeder BO
- Published
- 2022
- Full Text
- View/download PDF
10. Author Correction: Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice.
- Author
-
Keipert S, Lutter D, Schroeder BO, Brandt D, Ståhlman M, Schwarzmayr T, Graf E, Fuchs H, de Angelis MH, Tschöp MH, Rozman J, and Jastroch M
- Published
- 2021
- Full Text
- View/download PDF
11. Obesity-associated microbiota contributes to mucus layer defects in genetically obese mice.
- Author
-
Schroeder BO, Birchenough GMH, Pradhan M, Nyström EEL, Henricsson M, Hansson GC, and Bäckhed F
- Subjects
- Animals, Blood Glucose analysis, Colon metabolism, Colon microbiology, Colon pathology, Female, Glucose metabolism, Intestinal Mucosa microbiology, Intestinal Mucosa pathology, Mice, Mice, Inbred C57BL, Mice, Inbred NOD, Mice, Obese, Obesity genetics, Phenotype, Gastrointestinal Microbiome, Intestinal Mucosa metabolism, Obesity pathology
- Abstract
The intestinal mucus layer is a physical barrier separating the tremendous number of gut bacteria from the host epithelium. Defects in the mucus layer have been linked to metabolic diseases, but previous studies predominantly investigated mucus function during high-caloric/low-fiber dietary interventions, thus making it difficult to separate effects mediated directly through diet quality from potential obesity-dependent effects. As such, we decided to examine mucus function in mouse models with metabolic disease to distinguish these factors. Here we show that, in contrast to their lean littermates, genetically obese (ob/ob) mice have a defective inner colonic mucus layer that is characterized by increased penetrability and a reduced mucus growth rate. Exploiting the coprophagic behavior of mice, we next co-housed ob/ob and lean mice to investigate if the gut microbiota contributed to these phenotypes. Co-housing rescued the defect of the mucus growth rate, whereas mucus penetrability displayed an intermediate phenotype in both mouse groups. Of note, non-obese diabetic mice with high blood glucose levels displayed a healthy colonic mucus barrier, indicating that the mucus defect is obesity- rather than glucose-mediated. Thus, our data suggest that the gut microbiota community of obesity-prone mice may regulate obesity-associated defects in the colonic mucosal barrier, even in the presence of dietary fiber., Competing Interests: Conflict of interest—The authors declare that they have no conflicts of interest with the contents of this article., (© 2020 Schroeder et al.)
- Published
- 2020
- Full Text
- View/download PDF
12. Does an Apple a Day Also Keep the Microbes Away? The Interplay Between Diet, Microbiota, and Host Defense Peptides at the Intestinal Mucosal Barrier.
- Author
-
Puértolas-Balint F and Schroeder BO
- Subjects
- Animals, Humans, Malus, Antimicrobial Cationic Peptides immunology, Diet, Gastrointestinal Microbiome immunology, Intestinal Mucosa immunology
- Abstract
A crucial mechanism of intestinal defense includes the production and secretion of host defense peptides (HDPs). HDPs control pathogens and commensals at the intestinal interface by direct killing, by sequestering vital ions, or by causing bacterial cells to aggregate in the mucus layer. Accordingly, the combined activity of various HDPs neutralizes gut bacteria before reaching the mucosa and thus helps to maintain the homeostatic balance between the host and its microbes at the mucosal barrier. Defects in the mucosal barrier have been associated with various diseases that are on the rise in the Western world. These include metabolic diseases, such as obesity and type 2 diabetes, and inflammatory intestinal disorders, including ulcerative colitis and Crohn's disease, the two major entities of inflammatory bowel disease. While the etiology of these diseases is multifactorial, highly processed Western-style diet (WSD) that is rich in carbohydrates and fat and low in dietary fiber content, is considered to be a contributing lifestyle factor. As such, WSD does not only profoundly affect the resident microbes in the intestine, but can also directly alter HDP function, thereby potentially contributing to intestinal mucosal barrier dysfunction. In this review we aim to decipher the complex interaction between diet, microbiota, and HDPs. We discuss how HDP expression can be modulated by specific microbes and their metabolites as well as by dietary factors, including fibers, lipids, polyphenols and vitamins. We identify several dietary compounds that lead to reduced HDP function, but also factors that stimulate HDP production in the intestine. Furthermore, we argue that the effect of HDPs against commensal bacteria has been understudied when compared to pathogens, and that local environmental conditions also need to be considered. In addition, we discuss the known molecular mechanisms behind HDP modulation. We believe that a better understanding of the diet-microbiota-HDP interdependence will provide insights into factors underlying modern diseases and will help to identify potential dietary interventions or probiotic supplementation that can promote HDP-mediated intestinal barrier function in the Western gut., (Copyright © 2020 Puértolas-Balint and Schroeder.)
- Published
- 2020
- Full Text
- View/download PDF
13. Endogenous FGF21-signaling controls paradoxical obesity resistance of UCP1-deficient mice.
- Author
-
Keipert S, Lutter D, Schroeder BO, Brandt D, Ståhlman M, Schwarzmayr T, Graf E, Fuchs H, de Angelis MH, Tschöp MH, Rozman J, and Jastroch M
- Subjects
- Adipose Tissue, Brown metabolism, Adipose Tissue, White metabolism, Animals, Energy Metabolism, Fibroblast Growth Factors genetics, Humans, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Obesity genetics, Signal Transduction, Uncoupling Protein 1 genetics, Fibroblast Growth Factors metabolism, Obesity metabolism, Uncoupling Protein 1 metabolism
- Abstract
Uncoupling protein 1 (UCP1) executes thermogenesis in brown adipose tissue, which is a major focus of human obesity research. Although the UCP1-knockout (UCP1 KO) mouse represents the most frequently applied animal model to judge the anti-obesity effects of UCP1, the assessment is confounded by unknown anti-obesity factors causing paradoxical obesity resistance below thermoneutral temperatures. Here we identify the enigmatic factor as endogenous FGF21, which is primarily mediating obesity resistance. The generation of UCP1/FGF21 double-knockout mice (dKO) fully reverses obesity resistance. Within mild differences in energy metabolism, urine metabolomics uncover increased secretion of acyl-carnitines in UCP1 KOs, suggesting metabolic reprogramming. Strikingly, transcriptomics of metabolically important organs reveal enhanced lipid and oxidative metabolism in specifically white adipose tissue that is fully reversed in dKO mice. Collectively, this study characterizes the effects of endogenous FGF21 that acts as master regulator to protect from diet-induced obesity in the absence of UCP1.
- Published
- 2020
- Full Text
- View/download PDF
14. The Nlrp6 inflammasome is not required for baseline colonic inner mucus layer formation or function.
- Author
-
Volk JK, Nyström EEL, van der Post S, Abad BM, Schroeder BO, Johansson Å, Svensson F, Jäverfelt S, Johansson MEV, Hansson GC, and Birchenough GMH
- Subjects
- Animals, Colon metabolism, Colon microbiology, Gastrointestinal Microbiome immunology, Goblet Cells metabolism, Goblet Cells microbiology, Inflammasomes genetics, Inflammasomes metabolism, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Inflammatory Bowel Diseases metabolism, Interleukin-18 genetics, Interleukin-18 immunology, Interleukin-18 metabolism, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Mice, Inbred C57BL, Mice, Knockout, Mice, Transgenic, Mucin-2 immunology, Mucin-2 metabolism, Mucus metabolism, Mucus microbiology, Receptors, Cell Surface genetics, Receptors, Cell Surface metabolism, Signal Transduction immunology, Colon immunology, Goblet Cells immunology, Inflammasomes immunology, Intestinal Mucosa immunology, Mucus immunology, Receptors, Cell Surface immunology
- Abstract
The inner mucus layer (IML) is a critical barrier that protects the colonic epithelium from luminal threats and inflammatory bowel disease. Innate immune signaling is thought to regulate IML formation via goblet cell Nlrp6 inflammasome activity that controls secretion of the mucus structural component Muc2. We report that isolated colonic goblet cells express components of several inflammasomes; however, analysis of IML properties in multiple inflammasome-deficient mice, including littermate-controlled Nlrp6
-/- , detect a functional IML barrier in all strains. Analysis of mice lacking inflammasome substrate cytokines identifies a defective IML in Il18-/- mice, but this phenotype is ultimately traced to a microbiota-driven, Il18-independent effect. Analysis of phenotypic transfer between IML-deficient and IML-intact mice finds that the Bacteroidales family S24-7 (Muribaculaceae) and genus Adlercrutzia consistently positively covary with IML barrier function. Together, our results demonstrate that baseline IML formation and function is independent of inflammasome activity and highlights the role of the microbiota in determining IML barrier function., (© 2019 Volk et al.)- Published
- 2019
- Full Text
- View/download PDF
15. Microbiota and mucosal defense in IBD: an update.
- Author
-
Stange EF and Schroeder BO
- Subjects
- Animals, Anti-Bacterial Agents therapeutic use, Antimicrobial Cationic Peptides immunology, Antimicrobial Cationic Peptides metabolism, Colitis, Ulcerative drug therapy, Colitis, Ulcerative immunology, Colitis, Ulcerative metabolism, Crohn Disease drug therapy, Crohn Disease immunology, Crohn Disease metabolism, Dysbiosis, Host-Pathogen Interactions, Humans, Immunity, Mucosal, Intestinal Mucosa drug effects, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Mucus immunology, Mucus metabolism, Mucus microbiology, Probiotics therapeutic use, Colitis, Ulcerative microbiology, Crohn Disease microbiology, Gastrointestinal Microbiome drug effects, Intestinal Mucosa microbiology
- Abstract
Introduction : Inflammatory bowel diseases (IBD) are on the rise worldwide. This review covers the current concepts of the etiology of Crohn´s disease and ulcerative colitis by focusing on an unbalanced interaction between the intestinal microbiota and the mucosal barrier. Understanding these issues is of paramount importance for the development of targeted therapies aiming at the disease cause. Area covered : Gut microbiota alterations and a dysfunctional intestinal mucosa are associated with IBD. Here we focus on specific defense structures of the mucosal barrier, namely antimicrobial peptides and the mucus layer, which keep the gut microbiota at a distance under healthy conditions and are defective in IBD. Expert commentary : The microbiology of both forms of IBD is different but characterized by a reduced bacterial diversity and richness. Abundance of certain bacterial species is altered, and the compositional changes are related to disease activity. In IBD the mucus layer above the epithelium is contaminated by bacteria and the immune reaction is dominated by the antibacterial response. Human genetics suggest that many of the basic deficiencies in the mucosal response, due to Paneth cell, defensin and mucus defects, are primary. Nutrition may also be important but so far there is no therapy targeting the mucosal barrier.
- Published
- 2019
- Full Text
- View/download PDF
16. Proteolytic Degradation of reduced Human Beta Defensin 1 generates a Novel Antibiotic Octapeptide.
- Author
-
Wendler J, Schroeder BO, Ehmann D, Koeninger L, Mailänder-Sánchez D, Lemberg C, Wanner S, Schaller M, Stange EF, Malek NP, Weidenmaier C, LeibundGut-Landmann S, and Wehkamp J
- Subjects
- Bacteria growth & development, Fungi growth & development, Humans, Proteolysis, Anti-Bacterial Agents pharmacology, Bacteria drug effects, Fungi drug effects, Peptide Fragments pharmacology, beta-Defensins chemistry, beta-Defensins metabolism
- Abstract
Microbial resistance against clinical used antibiotics is on the rise. Accordingly, there is a high demand for new innovative antimicrobial strategies. The host-defense peptide human beta-defensin 1 (hBD-1) is produced continuously by epithelial cells and exhibits compelling antimicrobial activity after reduction of its disulphide bridges. Here we report that proteolysis of reduced hBD-1 by gastrointestinal proteases as well as human duodenal secretions produces an eight-amino acid carboxy-terminal fragment. The generated octapeptide retains antibiotic activity, yet with distinct characteristics differing from the full-length peptide. We modified the octapeptide by stabilizing its termini and by using non-natural D-amino acids. The native and modified peptide variants showed antibiotic activity against pathogenic as well as antibiotic-resistant microorganisms, including E. coli, P. aeruginosa and C. albicans. Moreover, in an in vitro C. albicans infection model the tested peptides demonstrated effective amelioration of C. albicans infection without showing cytotoxity on human cells. In summary, protease degradation of hBD-1 provides a yet unknown mechanism to broaden antimicrobial host defense, which could be used to develop defensin-derived therapeutic applications.
- Published
- 2019
- Full Text
- View/download PDF
17. Fight them or feed them: how the intestinal mucus layer manages the gut microbiota.
- Author
-
Schroeder BO
- Abstract
The intestinal tract is inhabited by a tremendous number of microorganisms, termed the gut microbiota. These microorganisms live in a mutualistic relationship with their host and assist in the degradation of complex carbohydrates. Although the gut microbiota is generally considered beneficial, the vast number of microbial cells also form a permanent threat to the host. Thus, the intestinal epithelium is covered with a dense layer of mucus to prevent translocation of the gut microbiota into underlying tissues. Intestinal mucus is an organized glycoprotein network with a host-specific glycan structure. While the mucus layer has long been considered a passive, host-designed barrier, recent studies showed that maturation and function of the mucus layer are strongly influenced by the gut microbiota. In return, the glycan repertoire of mucins can select for distinct mucosa-associated bacteria that are able to bind or degrade specific mucin glycans as a nutrient source. Because the intestinal mucus layer is at the crucial interface between host and microbes, its breakdown leads to gut bacterial encroachment that can eventually cause inflammation and infection. Accordingly, a dysfunctional mucus layer has been observed in colitis in mice and humans. Moreover, the increased consumption of a low-fiber Western-style diet in our modern society has recently been demonstrated to cause bacteria-mediated defects of the intestinal mucus layer. Here, I will review current knowledge on the interaction between gut bacteria and the intestinal mucus layer in health and disease. Understanding the molecular details of this host-microbe interaction may contribute to the development of novel treatment options for diseases involving a dysfunctional mucus layer, such as ulcerative colitis.
- Published
- 2019
- Full Text
- View/download PDF
18. Dietary destabilisation of the balance between the microbiota and the colonic mucus barrier.
- Author
-
Birchenough G, Schroeder BO, Bäckhed F, and Hansson GC
- Subjects
- Animals, Colon pathology, Colon physiopathology, Diet, Western adverse effects, Dietary Fiber administration & dosage, Inflammatory Bowel Diseases microbiology, Inflammatory Bowel Diseases prevention & control, Intestinal Mucosa pathology, Intestinal Mucosa physiopathology, Mice, Colon microbiology, Diet, Gastrointestinal Microbiome physiology, Intestinal Mucosa microbiology
- Abstract
It has long been acknowledged that dietary fibres are important to maintain a healthy gut. Over the past decade, several studies have shown that loss of complex polysaccharides from the Western diet has resulted in alterations to our colonic microbiota. The concurrent increase in the incidence of inflammatory bowel disease in the Western world has driven us to explore the potential mechanistic link between diet, the microbiota and the host defence systems that normally prevent inflammation. Using mice fed a low fibre Western-style diet and robust live tissue analytical methods we have now provided evidence that this diet impairs the colonic inner mucus layer that normally separates bacteria from host cells. Western societies urgently need to develop their understanding of the molecular mechanisms of the diet-microbiota-mucus axis and its implications for inflammatory diseases.
- Published
- 2019
- Full Text
- View/download PDF
19. Bacterial Periplasmic Oxidoreductases Control the Activity of Oxidized Human Antimicrobial β-Defensin 1.
- Author
-
Wendler J, Ehmann D, Courth L, Schroeder BO, Malek NP, and Wehkamp J
- Subjects
- Bacteria genetics, Bacteria immunology, Bacteria metabolism, Bacteria ultrastructure, Bacterial Infections immunology, Bacterial Infections metabolism, Bacterial Infections microbiology, Bacterial Proteins genetics, Escherichia coli genetics, Escherichia coli immunology, Escherichia coli metabolism, Host-Pathogen Interactions genetics, Host-Pathogen Interactions immunology, Humans, Immunity, Innate, Membranes metabolism, Models, Biological, Oxidation-Reduction, beta-Defensins genetics, beta-Defensins immunology, Bacterial Proteins metabolism, Oxidoreductases metabolism, Periplasmic Proteins metabolism, beta-Defensins metabolism
- Abstract
The antimicrobial peptide human β-defensin 1 (hBD1) is continuously produced by epithelial cells in many tissues. Compared to other defensins, hBD1 has only minor antibiotic activity in its native state. After reduction of its disulfide bridges, however, it becomes a potent antimicrobial agent against bacteria, while the oxidized native form (hBD1ox) shows specific activity against Gram-negative bacteria. We show that the killing mechanism of hBD1ox depends on aerobic growth conditions and bacterial enzymes. We analyzed the different activities of hBD1 using mutants of Escherichia coli lacking one or more specific proteins of their outer membrane, cytosol, or redox systems. We discovered that DsbA and DsbB are essential for the antimicrobial activity of hBD1ox but not for that of reduced hBD1 (hBD1red). Furthermore, our results strongly suggest that hBD1ox uses outer membrane protein FepA to penetrate the bacterial periplasm space. In contrast, other bacterial proteins in the outer membrane and cytosol did not modify the antimicrobial activity. Using immunogold labeling, we identified the localization of hBD1ox in the periplasmic space and partly in the outer membrane of E. coli However, in resistant mutants lacking DsbA and DsbB, hBD1ox was detected mainly in the bacterial cytosol. In summary, we discovered that hBD1ox could use FepA to enter the periplasmic space, where its activity depends on presence of DsbA and DsbB. HBD1ox concentrates in the periplasm in Gram-negative bacteria, which finally leads to bleb formation and death of the bacteria. Thus, the bacterial redox system plays an essential role in mechanisms of resistance against host-derived peptides such as hBD1., (Copyright © 2018 American Society for Microbiology.)
- Published
- 2018
- Full Text
- View/download PDF
20. Bifidobacteria or Fiber Protects against Diet-Induced Microbiota-Mediated Colonic Mucus Deterioration.
- Author
-
Schroeder BO, Birchenough GMH, Ståhlman M, Arike L, Johansson MEV, Hansson GC, and Bäckhed F
- Subjects
- Animals, Colon pathology, Dietary Supplements, Gastrointestinal Microbiome physiology, Intestinal Mucosa pathology, Inulin therapeutic use, Male, Mice, Mice, Inbred C57BL, Mice, Knockout, Obesity pathology, Bifidobacterium longum metabolism, Colon microbiology, Diet, Western adverse effects, Dietary Fiber therapeutic use, Fecal Microbiota Transplantation, Intestinal Mucosa microbiology
- Abstract
Diet strongly affects gut microbiota composition, and gut bacteria can influence the colonic mucus layer, a physical barrier that separates trillions of gut bacteria from the host. However, the interplay between a Western style diet (WSD), gut microbiota composition, and the intestinal mucus layer is less clear. Here we show that mice fed a WSD have an altered colonic microbiota composition that causes increased penetrability and a reduced growth rate of the inner mucus layer. Both barrier defects can be prevented by transplanting microbiota from chow-fed mice. In addition, we found that administration of Bifidobacterium longum was sufficient to restore mucus growth, whereas administration of the fiber inulin prevented increased mucus penetrability in WSD-fed mice. We hypothesize that the presence of distinct bacteria is crucial for proper mucus function. If confirmed in humans, these findings may help to better understand diseases with an affected mucus layer, such as ulcerative colitis., (Copyright © 2017 Elsevier Inc. All rights reserved.)
- Published
- 2018
- Full Text
- View/download PDF
21. Gram-positive bacteria are held at a distance in the colon mucus by the lectin-like protein ZG16.
- Author
-
Bergström JH, Birchenough GM, Katona G, Schroeder BO, Schütte A, Ermund A, Johansson ME, and Hansson GC
- Subjects
- Animals, Colon metabolism, Colon microbiology, Digestive System metabolism, Epithelial Cells metabolism, Epithelial Cells microbiology, Glycosylation, Gram-Positive Bacteria metabolism, Host-Pathogen Interactions genetics, Lectins metabolism, Mice, Mice, Knockout, Mucus metabolism, Mucus microbiology, Symbiosis genetics, Gram-Positive Bacteria genetics, Lectins genetics, Membrane Proteins genetics, Proteomics
- Abstract
The distal colon functions as a bioreactor and harbors an enormous amount of bacteria in a mutualistic relationship with the host. The microbiota have to be kept at a safe distance to prevent inflammation, something that is achieved by a dense inner mucus layer that lines the epithelial cells. The large polymeric nets made up by the heavily O-glycosylated MUC2 mucin forms this physical barrier. Proteomic analyses of mucus have identified the lectin-like protein ZG16 (zymogen granulae protein 16) as an abundant mucus component. To elucidate the function of ZG16, we generated recombinant ZG16 and studied Zg16
-/- mice. ZG16 bound to and aggregated Gram-positive bacteria via binding to the bacterial cell wall peptidoglycan. Zg16-/- mice have a distal colon mucus layer with normal thickness, but with bacteria closer to the epithelium. Using distal colon explants mounted in a horizontal perfusion chamber we demonstrated that treatment of bacteria with recombinant ZG16 hindered bacterial penetration into the mucus. The inner colon mucus of Zg16-/- animals had a higher load of Gram-positive bacteria and showed bacteria with higher motility in the mucus close to the host epithelium compared with cohoused littermate Zg16+/+ The more penetrable Zg16-/- mucus allowed Gram-positive bacteria to translocate to systemic tissues. Viable bacteria were found in spleen and were associated with increased abdominal fat pad mass in Zg16-/- animals. The function of ZG16 reveals a mechanism for keeping bacteria further away from the host colon epithelium., Competing Interests: The authors declare no conflict of interest.- Published
- 2016
- Full Text
- View/download PDF
22. Signals from the gut microbiota to distant organs in physiology and disease.
- Author
-
Schroeder BO and Bäckhed F
- Abstract
The ecosystem of the human gut consists of trillions of bacteria forming a bioreactor that is fueled by dietary macronutrients to produce bioactive compounds. These microbiota-derived metabolites signal to distant organs in the body, which enables the gut bacteria to connect to the immune and hormone system, to the brain (the gut-brain axis) and to host metabolism, as well as other functions of the host. This microbe-host communication is essential to maintain vital functions of the healthy host. Recently, however, the gut microbiota has been associated with a number of diseases, ranging from obesity and inflammatory diseases to behavioral and physiological abnormalities associated with neurodevelopmental disorders. In this Review, we will discuss microbiota-host cross-talk and intestinal microbiome signaling to extraintestinal organs. We will review mechanisms of how this communication might contribute to host physiology and discuss how misconfigured signaling might contribute to different diseases.
- Published
- 2016
- Full Text
- View/download PDF
23. Disulphide-reduced psoriasin is a human apoptosis-inducing broad-spectrum fungicide.
- Author
-
Hein KZ, Takahashi H, Tsumori T, Yasui Y, Nanjoh Y, Toga T, Wu Z, Grötzinger J, Jung S, Wehkamp J, Schroeder BO, Schroeder JM, and Morita E
- Subjects
- Animals, Aspergillosis drug therapy, Aspergillus fumigatus drug effects, Candida albicans drug effects, Disease Models, Animal, Guinea Pigs, Humans, Mice, Microbial Sensitivity Tests, Oxidation-Reduction, S100 Calcium Binding Protein A7, S100 Proteins chemistry, S100 Proteins therapeutic use, Antifungal Agents pharmacology, Apoptosis drug effects, Disulfides chemistry, S100 Proteins pharmacology
- Abstract
The unexpected resistance of psoriasis lesions to fungal infections suggests local production of an antifungal factor. We purified Trichophyton rubrum-inhibiting activity from lesional psoriasis scale extracts and identified the Cys-reduced form of S100A7/psoriasin (redS100A7) as a principal antifungal factor. redS100A7 inhibits various filamentous fungi, including the mold Aspergillus fumigatus, but not Candida albicans. Antifungal activity was inhibited by Zn(2+), suggesting that redS100A7 interferes with fungal zinc homeostasis. Because S100A7-mutants lacking a single cysteine are no longer antifungals, we hypothesized that redS100A7 is acting as a Zn(2+)-chelator. Immunogold electron microscopy studies revealed that it penetrates fungal cells, implicating possible intracellular actions. In support with our hypothesis, the cell-penetrating Zn(2+)-chelator TPEN was found to function as a broad-spectrum antifungal. Ultrastructural analyses of redS100A7-treated T. rubrum revealed marked signs of apoptosis, suggesting that its mode of action is induction of programmed cell death. TUNEL, SYTOX-green analyses, and caspase-inhibition studies supported this for both T. rubrum and A. fumigatus. Whereas redS100A7 can be generated from oxidized S100A7 by action of thioredoxin or glutathione, elevated redS100A7 levels in fungal skin infection indicate induction of both S100A7 and its reducing agent in vivo. To investigate whether redS100A7 and TPEN are antifungals in vivo, we used a guinea pig tinea pedes model for fungal skin infections and a lethal mouse Aspergillus infection model for lung infection and found antifungal activity in both in vivo animal systems. Thus, selective fungal cell-penetrating Zn(2+)-chelators could be useful as an urgently needed novel antifungal therapeutic, which induces programmed cell death in numerous fungi.
- Published
- 2015
- Full Text
- View/download PDF
24. Paneth cell α-defensin 6 (HD-6) is an antimicrobial peptide.
- Author
-
Schroeder BO, Ehmann D, Precht JC, Castillo PA, Küchler R, Berger J, Schaller M, Stange EF, and Wehkamp J
- Subjects
- Anti-Bacterial Agents chemical synthesis, Bacteroides drug effects, Bacteroides growth & development, Bacteroides ultrastructure, Bifidobacterium drug effects, Bifidobacterium growth & development, Bifidobacterium ultrastructure, Candida albicans drug effects, Candida albicans growth & development, Candida albicans ultrastructure, Escherichia drug effects, Escherichia growth & development, Escherichia ultrastructure, Humans, Hydrogen-Ion Concentration, Lactobacillus acidophilus drug effects, Lactobacillus acidophilus growth & development, Lactobacillus acidophilus ultrastructure, Microbial Sensitivity Tests, Oxidation-Reduction, Paneth Cells immunology, Paneth Cells metabolism, Pseudomonas aeruginosa drug effects, Pseudomonas aeruginosa growth & development, Pseudomonas aeruginosa ultrastructure, Salmonella enterica drug effects, Salmonella enterica growth & development, Salmonella enterica ultrastructure, Staphylococcus drug effects, Staphylococcus growth & development, Staphylococcus ultrastructure, Streptococcus drug effects, Streptococcus growth & development, Streptococcus ultrastructure, alpha-Defensins chemical synthesis, Anti-Bacterial Agents pharmacology, alpha-Defensins pharmacology
- Abstract
Defensins protect human barriers from commensal and pathogenic microorganisms. Human α-defensin 6 (HD-6) is produced exclusively by small intestinal Paneth cells but, in contrast to other antimicrobial peptides (AMPs) for HD-6, no direct antibacterial killing activity has been detected so far. Herein, we systematically tested how environmental factors, like pH and reducing conditions, affect antimicrobial activity of different defensins against anaerobic bacteria of the human intestinal microbiota. Remarkably, by mimicking the intestinal milieu we detected for the first time antibacterial activity of HD-6. Activity was observed against anaerobic gut commensals but not against some pathogenic strains. Antibiotic activity was attributable to the reduced peptide and independent of free cysteines or a conserved histidine residue. Furthermore, the oxidoreductase thioredoxin, which is also expressed in Paneth cells, is able to reduce a truncated physiological variant of HD-6. Ultrastructural analyses revealed that reduced HD-6 causes disintegration of cytoplasmic structures and alterations in the bacterial cell envelope, while maintaining extracellular net-like structures. We conclude that HD-6 is an antimicrobial peptide. Our data suggest two distinct antimicrobial mechanisms by one peptide: HD-6 kills specific microbes depending on the local environmental conditions, whereas known microbial trapping by extracellular net structures is independent of the reducing milieu.
- Published
- 2015
- Full Text
- View/download PDF
25. Cell-mediated reduction of human β-defensin 1: a major role for mucosal thioredoxin.
- Author
-
Jaeger SU, Schroeder BO, Meyer-Hoffert U, Courth L, Fehr SN, Gersemann M, Stange EF, and Wehkamp J
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Auranofin pharmacology, Bodily Secretions drug effects, Caco-2 Cells, Cell Communication, Cellular Microenvironment, Female, Humans, Immunity, Cellular drug effects, Immunity, Cellular genetics, Intestinal Mucosa drug effects, Male, Middle Aged, Oxidation-Reduction drug effects, RNA, Small Interfering genetics, Thioredoxins antagonists & inhibitors, Thioredoxins genetics, Young Adult, beta-Defensins genetics, Anti-Infective Agents metabolism, Inflammatory Bowel Diseases immunology, Intestinal Mucosa immunology, Thioredoxins metabolism, beta-Defensins metabolism
- Abstract
Human β-defensin 1 (hBD-1) is an antimicrobial peptide expressed by epithelia and hematopoietic cells. We demonstrated recently that hBD-1 shows activity against enteric commensals and Candida species only after its disulfide bonds have been reduced by thioredoxin (TRX) or a reducing environment. Here we show that besides TRX, glutaredoxin (GRX) is also able to reduce hBD-1, although with far less efficacy. Moreover, living intestinal and lymphoid cells can effectively catalyze reduction of extracellular hBD-1. By chemical inhibition of the TRX system or specific knockdown of TRX, we demonstrate that cell-mediated reduction is largely dependent on TRX. Quantitative PCR in intestinal tissues of healthy controls and inflammatory bowel disease patients revealed altered expression of some, although not all, redox enzymes, especially in ulcerative colitis. Reduced hBD-1 and TRX localize to extracellular colonic mucus, suggesting that secreted or membrane-bound TRX converts hBD-1 to a potent antimicrobial peptide in vivo.
- Published
- 2013
- Full Text
- View/download PDF
26. Antimicrobial activity of high-mobility-group box 2: a new function to a well-known protein.
- Author
-
Küchler R, Schroeder BO, Jaeger SU, Stange EF, and Wehkamp J
- Subjects
- Blotting, Western, Caco-2 Cells, Chromatography, High Pressure Liquid, HMGB2 Protein genetics, Humans, Immunohistochemistry, In Vitro Techniques, Intestinal Mucosa metabolism, Leukocytes, Mononuclear metabolism, Microbial Sensitivity Tests, Escherichia coli drug effects, HMGB2 Protein metabolism
- Abstract
The human intestinal tract is highly colonized by a vast number of microorganisms. Despite this permanent challenge, infections remain rare, due to a very effective barrier defense system. Essential effectors of this system are antimicrobial peptides and proteins (AMPs), which are secreted by intestinal epithelial and lymphoid cells, balance the gut microbial community, and prevent the translocation of microorganisms. Several antimicrobial proteins have already been identified in the gut. Nonetheless, we hypothesized that additional AMPs are yet to be discovered in this setting. Using biological screening based on antimicrobial function, here we identified competent antibacterial activity of high-mobility-group box 2 (HMGB2) against Escherichia coli. By recombinant expression, we confirmed this biologically new antimicrobial activity against different commensal and pathogenic bacteria. In addition, we demonstrated that the two DNA-binding domains (HMG boxes A and B) are crucial for the antibiotic function. We detected HMGB2 in several gastrointestinal tissues by mRNA analysis and immunohistochemical staining. In addition to the nuclei, we also observed HMGB2 in the cytoplasm of intestinal epithelial cells. Furthermore, HMGB2 was detectable in vitro in the supernatants of two different cell types, supporting an extracellular function. HMGB2 expression was not changed in inflammatory bowel disease but was detected in certain stool samples of patients, whereas it was absent from control individuals. Taken together, we characterized HMGB2 as an antimicrobial protein in intestinal tissue, complementing the diverse repertoire of gut mucosal defense molecules.
- Published
- 2013
- Full Text
- View/download PDF
27. Gastric antimicrobial peptides fail to eradicate Helicobacter pylori infection due to selective induction and resistance.
- Author
-
Nuding S, Gersemann M, Hosaka Y, Konietzny S, Schaefer C, Beisner J, Schroeder BO, Ostaff MJ, Saigenji K, Ott G, Schaller M, Stange EF, and Wehkamp J
- Subjects
- Adult, Aged, Aged, 80 and over, Antimicrobial Cationic Peptides genetics, Antimicrobial Cationic Peptides pharmacology, Cathelicidins genetics, Cathelicidins metabolism, Cathelicidins pharmacology, Disk Diffusion Antimicrobial Tests, Elafin genetics, Elafin metabolism, Elafin pharmacology, Female, Gastric Mucosa pathology, Gastritis genetics, Gastritis metabolism, Gastritis microbiology, Gastritis pathology, Gene Expression Regulation, Helicobacter Infections genetics, Humans, Male, Middle Aged, Young Adult, beta-Defensins genetics, beta-Defensins metabolism, beta-Defensins pharmacology, Antimicrobial Cationic Peptides metabolism, Disease Resistance, Gastric Mucosa metabolism, Gastric Mucosa microbiology, Helicobacter Infections metabolism, Helicobacter Infections microbiology, Helicobacter pylori drug effects
- Abstract
Background: Although antimicrobial peptides protect mucus and mucosa from bacteria, Helicobacter pylori is able to colonize the gastric mucus. To clarify in which extend Helicobacter escapes the antimicrobial defense, we systematically assessed susceptibility and expression levels of different antimicrobial host factors in gastric mucosa with and without H. pylori infection., Materials and Methods: We investigated the expression levels of HBD1 (gene name DEFB1), HBD2 (DEFB4A), HBD3 (DEFB103A), HBD4 (DEFB104A), LL37 (CAMP) and elafin (PI3) by real time PCR in gastric biopsy samples in a total of 20 controls versus 12 patients colonized with H. pylori. Immunostaining was performed for HBD2 and HBD3. We assessed antimicrobial susceptibility by flow cytometry, growth on blood agar, radial diffusion assay and electron microscopy., Results: H. pylori infection was associated with increased gastric levels of the inducible defensin HBD2 and of the antiprotease elafin, whereas the expression levels of the constitutive defensin HBD1, inducible HBD3 and LL37 remained unchanged. HBD4 was not expressed in significant levels in gastric mucosa. H. pylori strains were resistant to the defensins HBD1 as well as to elafin, and strain specific minimally susceptible to HBD2, whereas HBD3 and LL37 killed all H. pylori strains effectively. We demonstrated the binding of HBD2 and LL37 on the surface of H. pylori cells. Comparing the antibacterial activity of extracts from H. pylori negative and positive biopsies, we found only a minimal killing against H. pylori that was not increased by the induction of HBD2 in H. pylori positive samples., Conclusion: These data support the hypothesis that gastric H. pylori evades the host defense shield to allow colonization.
- Published
- 2013
- Full Text
- View/download PDF
28. More than a marine propeller--the flagellum of the probiotic Escherichia coli strain Nissle 1917 is the major adhesin mediating binding to human mucus.
- Author
-
Troge A, Scheppach W, Schroeder BO, Rund SA, Heuner K, Wehkamp J, Stange EF, and Oelschlaeger TA
- Subjects
- Animals, Female, Gluconates metabolism, Humans, Intestinal Mucosa microbiology, Mice, Mice, Inbred C57BL, Mucus chemistry, Swine, Adhesins, Bacterial metabolism, Bacterial Adhesion, Escherichia coli physiology, Flagella physiology, Mucus microbiology
- Abstract
The flagellum of the probiotic Escherichia coli strain Nissle 1917 (EcN) is not just responsible for motility, but also for EcN's ability to induce the production of human β-defensin 2. Here, we report a third function of this EcN organell. In this study we investigated the role of the EcN flagellum in adhesion to different host tissues by ex vivo and in vitro studies. Ex vivo studies with cryosections of human gut biopsies revealed that the flagellum of EcN is most likely important for efficient adhesion to the human intestinal tract. These results and in vitro studies with different epithelial cells indicated that the presence of mucus is important for efficient mediation of adhesion by the flagellum of EcN. We observed direct interaction between isolated flagella from EcN wild type and porcine mucin 2 as well as human mucus. However, we could not observe any interaction of the flagella with murine mucus. For the first time, we identified the mucus component gluconate as one receptor for the binding of flagella from EcN and were able to exclude the flagellin domain D3 as a responsible interaction partner. We propose that the flagellum of EcN is its major adhesin in vivo, which enables this probiotic strain to compete efficiently for binding sites on host tissue with several bacterial pathogens., (Copyright © 2012 Elsevier GmbH. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
29. [Human beta-defensin 1: from defence to offence].
- Author
-
Schroeder BO, Stange EF, and Wehkamp J
- Subjects
- Gene Expression Regulation genetics, Humans, Immunity, Mucosal immunology, Oxidation-Reduction, Virulence immunology, Bacteria immunology, Bacteria pathogenicity, Bacterial Translocation immunology, Immunity, Innate immunology, Inflammatory Bowel Diseases genetics, Inflammatory Bowel Diseases immunology, Intestinal Mucosa immunology, Intestinal Mucosa microbiology, Polymorphism, Genetic genetics, beta-Defensins genetics
- Abstract
The human gut is colonised by about one kilogram of commensal bacteria. These microorganisms are a potential threat, thus an efficient defence system is crucial in preventing bacterial translocation and infection. Besides other mechanisms of protection humans produce antimicrobial peptides (AMPs) that are able to kill a broad range of microorganisms. The human beta-defensin 1 (hBD-1) plays a major role because it is produced constitutively by all human epithelia and some immune cells. In contrast to other AMPs, however, the biological function of hBD-1 has remained unclear since the antibiotic activity of hBD-1 in vitro was only marginal. But still, several diseases have been associated with genetic polymorphisms in the hBD-1 encoding gene. Herein we discuss why the biological role of hBD-1 has been overlooked and how hBD-1 can be activated by chemical reduction. We elaborate on the biological significance of this activation and its importance for inflammatory bowel disease., (© Georg Thieme Verlag KG Stuttgart · New York.)
- Published
- 2012
- Full Text
- View/download PDF
30. Waking the wimp: redox-modulation activates human beta-defensin 1.
- Author
-
Schroeder BO, Stange EF, and Wehkamp J
- Subjects
- Amino Acid Sequence, Fungi, Gram-Negative Bacteria, Humans, Molecular Sequence Data, Oxidation-Reduction, Sequence Alignment, beta-Defensins chemistry, beta-Defensins genetics, beta-Defensins metabolism, beta-Defensins immunology
- Published
- 2011
- Full Text
- View/download PDF
31. Reduction of disulphide bonds unmasks potent antimicrobial activity of human β-defensin 1.
- Author
-
Schroeder BO, Wu Z, Nuding S, Groscurth S, Marcinowski M, Beisner J, Buchner J, Schaller M, Stange EF, and Wehkamp J
- Subjects
- Amino Acid Sequence, Anti-Infective Agents chemistry, Anti-Infective Agents immunology, Bifidobacterium drug effects, Bifidobacterium immunology, Biocatalysis, Candida albicans drug effects, Candida albicans immunology, Colon immunology, Colon metabolism, Colon microbiology, Disulfides chemistry, Dithiothreitol pharmacology, Humans, Immunity, Innate, Intestinal Mucosa immunology, Intestinal Mucosa metabolism, Intestinal Mucosa microbiology, Lactobacillus drug effects, Lactobacillus immunology, Molecular Sequence Data, Oxidation-Reduction drug effects, Oxygen metabolism, Partial Pressure, Protein Conformation drug effects, Thioredoxins metabolism, beta-Defensins chemistry, beta-Defensins immunology, Anti-Infective Agents metabolism, Anti-Infective Agents pharmacology, Disulfides metabolism, beta-Defensins metabolism, beta-Defensins pharmacology
- Abstract
Human epithelia are permanently challenged by bacteria and fungi, including commensal and pathogenic microbiota. In the gut, the fraction of strict anaerobes increases from proximal to distal, reaching 99% of bacterial species in the colon. At colonic mucosa, oxygen partial pressure is below 25% of airborne oxygen content, moreover microbial metabolism causes reduction to a low redox potential of -200 mV to -300 mV in the colon. Defensins, characterized by three intramolecular disulphide-bridges, are key effector molecules of innate immunity that protect the host from infectious microbes and shape the composition of microbiota at mucosal surfaces. Human β-defensin 1 (hBD-1) is one of the most prominent peptides of its class but despite ubiquitous expression by all human epithelia, comparison with other defensins suggested only minor antibiotic killing activity. Whereas much is known about the activity of antimicrobial peptides in aerobic environments, data about reducing environments are limited. Herein we show that after reduction of disulphide-bridges hBD-1 becomes a potent antimicrobial peptide against the opportunistic pathogenic fungus Candida albicans and against anaerobic, Gram-positive commensals of Bifidobacterium and Lactobacillus species. Reduced hBD-1 differs structurally from oxidized hBD-1 and free cysteines in the carboxy terminus seem important for the bactericidal effect. In vitro, the thioredoxin (TRX) system is able to reduce hBD-1 and TRX co-localizes with reduced hBD-1 in human epithelia. Hence our study indicates that reduced hBD-1 shields the healthy epithelium against colonisation by commensal bacteria and opportunistic fungi. Accordingly, an intimate interplay between redox-regulation and innate immune defence seems crucial for an effective barrier protecting human epithelia.
- Published
- 2011
- Full Text
- View/download PDF
32. Probiotic E. coli treatment mediates antimicrobial human beta-defensin synthesis and fecal excretion in humans.
- Author
-
Möndel M, Schroeder BO, Zimmermann K, Huber H, Nuding S, Beisner J, Fellermann K, Stange EF, and Wehkamp J
- Subjects
- Anti-Bacterial Agents therapeutic use, Caco-2 Cells, Escherichia coli drug effects, Humans, Microbial Viability drug effects, Probiotics therapeutic use, Species Specificity, Anti-Bacterial Agents pharmacology, Escherichia coli physiology, Feces chemistry, Probiotics pharmacology, beta-Defensins metabolism
- Abstract
Inducible epithelial human beta-defensins (hBD) play an important role in intestinal barrier function. In vitro studies showed that clinically effective probiotics induce antimicrobial hBD-2. Here, we aimed to assess the in vivo effect in healthy volunteers and also addressed how defensins affect probiotic survival. Symbioflor 2 containing one strain of several viable genotypes of Escherichia coli was administered to 23 healthy individuals. After 3 weeks, fecal hBD-2 peptide was increased in 78% (mean 3.7-fold; P<0.0001). Interestingly, the fecal hBD-2 peptide was still elevated 9 weeks after treatment (P=0.008). In vitro studies revealed that this effect was mediated by only one out of three tested E. coli genotypes and comparable to probiotic E. coli Nissle 1917 (10- to 15-fold). Functional assays showed that all tested bacteria were similarly killed by defensins allowing to speculate about a suicidal character of this effect. Defensin induction seems to be a common and important mechanism of probiotic treatment.
- Published
- 2009
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.